| name | Parathyroid Hormone Analogs |
| classification | Hormonal Agents, Bone Metabolism Modifiers |
| pharmacokinetics | The absorption, distribution, metabolism, and excretion of parathyroid hormone analogs vary depending on the specific analog. Generally, these drugs are administered subcutaneously. They are rapidly metabolized, primarily by the kidneys, with elimination half-lives varying between analogs. Some analogs have a greater affinity for the parathyroid hormone receptor and achieve a longer duration of action. |
| suggested dosage | Dosage is highly variable and should be determined by a healthcare professional based on individual patient factors. There is no single standard dosage. |
| indications | | 1 | Treatment of osteoporosis, particularly in postmenopausal women and men with high fracture risk. | | 2 | Treatment of hypoparathyroidism, in conjunction with calcium and vitamin D supplementation. | | 3 | Treatment of Paget's disease of bone (in selected cases). | | 4 | Potential role in bone loss associated with other conditions (e.g., glucocorticoid use, renal failure). |
|
| safety in pregnancy | Parathyroid hormone analogs are generally contraindicated in pregnancy due to potential risks to fetal skeletal development. Consult a healthcare professional to assess potential benefits and risks if pregnancy is considered or occurs during treatment. |
| safety in breastfeeding | Limited data exist on the safety and excretion of parathyroid hormone analogs in breast milk. Therefore, parathyroid hormone analogs are generally not recommended for use during breastfeeding. |
| side effects | | 1 | Headache | | 2 | Nausea | | 3 | Dizziness | | 4 | Leg cramps | | 5 | Skin reactions (e.g., rash, erythema, pruritus) | | 6 | Hypercalcemia (high blood calcium levels) | | 7 | Transient elevation in serum phosphate | | 8 | Bone pain | | 9 | Gastrointestinal upset (e.g., diarrhea, constipation) | | 10 | Transient, mild elevation in blood pressure |
|
| alternatives | |
| contraindications | | 1 | Hypersensitivity to the drug or any of its components. | | 2 | Severe hypercalcemia. | | 3 | Severe renal insufficiency. | | 4 | History of significant bone or eye disorders (very rare). |
|
| interactions | | 1 | Concurrent use of thiazide diuretics may increase the risk of hypercalcemia. | | 2 | Concurrent use of calcium and vitamin D supplements may potentiate the effects (especially in hypoparathyroidism). | | 3 | Consult a healthcare professional for specific drug interactions. |
|
| warnings and precautions | | 1 | Regular monitoring of blood calcium levels is essential. | | 2 | Monitor for side effects, especially in patients with pre-existing conditions. | | 3 | Assess risk of osteosarcoma (extremely rare), especially in patients with Paget's disease receiving long-term therapy. | | 4 | Inform the healthcare provider about all medications and supplements. | | 5 | Regular bone density monitoring may be required. |
|
| additional informations | | 1 | Different analogs have different durations of action and routes of administration. | | 2 | Always consult a healthcare professional before using. |
|
| patient information | | Disclaimer | This information is for general knowledge only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis, treatment, and personalized recommendations regarding parathyroid hormone analogs. |
|
